<mods xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd"><id>2954394</id><setSpec>journal_article</setSpec><setSpec>doc-type:article</setSpec><setSpec>ddc:540</setSpec><setSpec>journal_articleFtxt</setSpec><setSpec>open_access</setSpec>

<genre>article</genre>

<titleInfo><title>Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model</title></titleInfo>


<note type="publicationStatus">published</note>


<note type="qualityControlled">yes</note>

<name type="personal">
  <namePart type="given">Nicolo Michele</namePart>
  <namePart type="family">Tonali</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">92993407</identifier></name>
<name type="personal">
  <namePart type="given">Loreen</namePart>
  <namePart type="family">Hericks</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">184110715</identifier></name>
<name type="personal">
  <namePart type="given">David C.</namePart>
  <namePart type="family">Schröder</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">117057070</identifier><description xsi:type="identifierDefinition" type="orcid">0000-0002-7249-4156</description></name>
<name type="personal">
  <namePart type="given">Oliver</namePart>
  <namePart type="family">Kracker</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">53814480</identifier></name>
<name type="personal">
  <namePart type="given">Radoslaw</namePart>
  <namePart type="family">Krzemieniecki</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Julia</namePart>
  <namePart type="family">Kaffy</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Vadim</namePart>
  <namePart type="family">Le Joncour</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Pirjo</namePart>
  <namePart type="family">Laakkonen</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Antoine</namePart>
  <namePart type="family">Marion</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Sandrine</namePart>
  <namePart type="family">Ongeri</namePart>
  <role><roleTerm type="text">author</roleTerm> </role></name>
<name type="personal">
  <namePart type="given">Veronica Isabel</namePart>
  <namePart type="family">Dodero</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">60679852</identifier><description xsi:type="identifierDefinition" type="orcid">0000-0001-7937-1880</description></name>
<name type="personal">
  <namePart type="given">Norbert</namePart>
  <namePart type="family">Sewald</namePart>
  <role><roleTerm type="text">author</roleTerm> </role><identifier type="local">20281</identifier><description xsi:type="identifierDefinition" type="orcid">0000-0002-0309-2655</description></name>







<name type="corporate">
  <namePart/>
  <identifier type="local">17977</identifier>
  <role>
    <roleTerm type="text">department</roleTerm>
  </role>
</name>








<abstract lang="eng">In peptidotriazolamers every second peptide bond is replaced by a 1H-1,2,3-triazole. Such foldamers are expected to bridge the gap in molecular weight between small-molecule drugs and protein-based drugs. Amyloid beta (Abeta) aggregates play an important role in Alzheimer's disease. We studied the impact of amide bond replacements by 1,4-disubstituted 1H-1,2,3-triazoles on the inhibitory activity of the aggregation "hot spots" K16 LVFF20 and G39 VVIA42 in Abeta(1-42). We found that peptidotriazolamers act as modulators of the Abeta(1-42) oligomerization. Some peptidotriazolamers are able to interfere with the formation of toxic early Abeta oligomers, depending on the position of the triazoles, which is also supported by computational studies. Preliminary in vitro results demonstrate that a highly active peptidotriazolamer is also able to cross the blood-brain-barrier. © 2021 The Authors. ChemPlusChem published by Wiley-VCH GmbH.</abstract>

<relatedItem type="constituent">
  <location>
    <url displayLabel="cplu.202000814.pdf">https://pub.uni-bielefeld.de/download/2954394/2957771/cplu.202000814.pdf</url>
  </location>
  <physicalDescription><internetMediaType>application/pdf</internetMediaType></physicalDescription>
  <accessCondition type="restrictionOnAccess">no</accessCondition>
</relatedItem>
<originInfo><publisher>Wiley</publisher><dateIssued encoding="w3cdtf">2021</dateIssued>
</originInfo>
<language><languageTerm authority="iso639-2b" type="code">eng</languageTerm>
</language>



<relatedItem type="host"><titleInfo><title>ChemPlusChem</title></titleInfo>
  <identifier type="eIssn">2192-6506</identifier>
  <identifier type="MEDLINE">33905181</identifier>
  <identifier type="ISI">000647850200001</identifier><identifier type="urn">urn:nbn:de:0070-pub-29543940</identifier><identifier type="doi">10.1002/cplu.202000814</identifier>
<part><detail type="volume"><number>86</number></detail><detail type="issue"><number>6</number></detail><extent unit="pages">840-851</extent>
</part>
</relatedItem>
<relatedItem type="Supplementary material">
  <location>     <url>https://pub.uni-bielefeld.de/record/2956968</url>  </location>
</relatedItem>

<extension>
<bibliographicCitation>
<harvard1>Tonali, N.M., et al., 2021. Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. &lt;em&gt;ChemPlusChem&lt;/em&gt;, 86(6), p 840-851.</harvard1>
<ieee> N.M. Tonali, et al., “Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model”, &lt;em&gt;ChemPlusChem&lt;/em&gt;,  vol. 86, 2021,  pp. 840-851.</ieee>
<apa>Tonali, N. M., Hericks, L., Schröder, D. C., Kracker, O., Krzemieniecki, R., Kaffy, J., Le Joncour, V., et al. (2021). Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. &lt;em&gt;ChemPlusChem&lt;/em&gt;, &lt;em&gt;86&lt;/em&gt;(6), 840-851. &lt;a href="https://doi.org/10.1002/cplu.202000814" target="_blank"&gt;https://doi.org/10.1002/cplu.202000814&lt;/a&gt;</apa>
<wels>Tonali, N. M.; Hericks, L.; Schröder, D. C.; Kracker, O.; Krzemieniecki, R.; Kaffy, J.; Le Joncour, V.; Laakkonen, P.; Marion, A.; Ongeri, S.; Dodero, V. I.; Sewald, N. (2021): Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model &lt;em&gt;ChemPlusChem&lt;/em&gt;,86:(6): 840-851.</wels>
<apa_indent>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Tonali, N. M., Hericks, L., Schröder, D. C., Kracker, O., Krzemieniecki, R., Kaffy, J., Le Joncour, V., et al. (2021). Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. &lt;em&gt;ChemPlusChem&lt;/em&gt;, &lt;em&gt;86&lt;/em&gt;(6), 840-851. &lt;a href="https://doi.org/10.1002/cplu.202000814" target="_blank"&gt;https://doi.org/10.1002/cplu.202000814&lt;/a&gt;&lt;/div&gt;</apa_indent>
<mla>Tonali, Nicolo Michele, Hericks, Loreen, Schröder, David C., Kracker, Oliver, Krzemieniecki, Radoslaw, Kaffy, Julia, Le Joncour, Vadim, Laakkonen, Pirjo, Marion, Antoine, Ongeri, Sandrine, Dodero, Veronica Isabel, and Sewald, Norbert. “Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model”. &lt;em&gt;ChemPlusChem&lt;/em&gt; 86.6 (2021): 840-851.</mla>
<frontiers>Tonali, N. M., Hericks, L., Schröder, D. C., Kracker, O., Krzemieniecki, R., Kaffy, J., Le Joncour, V., Laakkonen, P., Marion, A., Ongeri, S., et al. (2021). Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. &lt;em&gt;ChemPlusChem&lt;/em&gt; 86, 840-851.</frontiers>
<default>Tonali NM, Hericks L, Schröder DC, Kracker O, Krzemieniecki R, Kaffy J, Le Joncour V, Laakkonen P, Marion A, Ongeri S, Dodero VI, et al. (2021) &lt;br /&gt;&lt;em&gt;ChemPlusChem&lt;/em&gt; 86(6): 840-851.</default>
<ama>Tonali NM, Hericks L, Schröder DC, et al. Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. &lt;em&gt;ChemPlusChem&lt;/em&gt;. 2021;86(6):840-851.</ama>
<lncs> Tonali, N.M., Hericks, L., Schröder, D.C., Kracker, O., Krzemieniecki, R., Kaffy, J., Le Joncour, V., Laakkonen, P., Marion, A., Ongeri, S., Dodero, V.I., Sewald, N.: Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. ChemPlusChem. 86, 840-851 (2021).</lncs>
<chicago>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Tonali, Nicolo Michele, Hericks, Loreen, Schröder, David C., Kracker, Oliver, Krzemieniecki, Radoslaw, Kaffy, Julia, Le Joncour, Vadim, et al. 2021. “Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model”. &lt;em&gt;ChemPlusChem&lt;/em&gt; 86 (6): 840-851.&lt;/div&gt;</chicago>
<dgps>&lt;div style="text-indent:-25px; padding-left:25px;padding-bottom:0px;"&gt;Tonali, N.M., Hericks, L., Schröder, D.C., Kracker, O., Krzemieniecki, R., Kaffy, J., Le Joncour, V., Laakkonen, P., Marion, A., Ongeri, S., Dodero, V.I. &amp;amp; Sewald, N. (2021). Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. &lt;em&gt;ChemPlusChem&lt;/em&gt;, &lt;em&gt;86&lt;/em&gt;(6), 840-851. Wiley. doi:10.1002/cplu.202000814.&lt;/div&gt;</dgps>
<angewandte-chemie>N. M.  Tonali, L.  Hericks, D. C.  Schröder, O.  Kracker, R.  Krzemieniecki, J.  Kaffy, V.  Le Joncour, P.  Laakkonen, A.  Marion, S.  Ongeri, et al., “Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model”, &lt;em&gt;ChemPlusChem&lt;/em&gt;, &lt;strong&gt;2021&lt;/strong&gt;, &lt;em&gt;86&lt;/em&gt;, 840-851.</angewandte-chemie>
<bio1>Tonali NM, Hericks L, Schröder DC, Kracker O, Krzemieniecki R, Kaffy J, Le Joncour V, Laakkonen P, Marion A, Ongeri S, Dodero VI, Sewald N (2021) &lt;br /&gt;Peptidotriazolamers Inhibit Abeta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model.&lt;br /&gt;ChemPlusChem 86(6): 840-851.</bio1>
</bibliographicCitation>
</extension>
<recordInfo><recordIdentifier>2954394</recordIdentifier><recordCreationDate encoding="w3cdtf">2021-05-03T09:44:29Z</recordCreationDate><recordChangeDate encoding="w3cdtf">2021-09-27T14:54:55Z</recordChangeDate>
</recordInfo>
</mods>